Pfizer PFE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.7B-9.3% | —— | $3.55B-20.6% | $2.93B+6,000% | $2.97B-4.8% | ||
| $1.61B-0.3% | $1.69B-5.8% | $1.66B-5.3% | $1.63B-6.1% | $1.62B-6.8% | ||
| $272M+60.0% | $225M+27.1% | $201M-26.6% | $203M-1.5% | $170M-22.7% | ||
| -$12M+98.2% | -$433M-9.3% | -$765M-58.7% | -$272M+65.3% | -$663M-50.3% | ||
| —— | $65.75M+141% | $65.75M+141% | $65.75M+141% | $65.75M+141% | ||
| —— | -$140.25M-166% | -$140.25M-166% | -$140.25M-166% | -$140.25M-166% | ||
| —— | -$117.25M+54.2% | -$117.25M+54.2% | -$117.25M+54.2% | -$117.25M+54.2% | ||
| —— | -$322.25M+61.9% | -$322.25M+61.9% | -$322.25M+61.9% | -$322.25M+61.9% | ||
| —— | -$916.75M-17.7% | -$916.75M-17.7% | -$916.75M-17.7% | -$916.75M-17.7% | ||
| —— | -$701.25M-109% | -$701.25M-109% | -$701.25M-109% | -$701.25M-109% | ||
| $2.62B+12.0% | $5.35B-20.4% | $4.6B-31.4% | $0+100% | $2.34B+114% | ||
| $436M-22.7% | $845M-7.9% | $602M-7.5% | $618M-3.0% | $564M-19.9% | ||
| $785M-76.0% | -$6.15B— | -$2.43B— | $3.95B-14.1% | $3.27B+89.0% | ||
| -$2.86B+45.4% | $0+100% | -$2.48B+46.6% | -$3.2B-30.0% | -$5.23B-6.0% | ||
| $19M+371% | $5M+117% | $2M— | $41M+328% | -$7M+75.0% | ||
| $563M+50.1% | —— | —— | $213M— | $375M+118% | ||
| $293M-17.0% | $981M-29.6% | $275M-1.8% | $1.13B-0.7% | $353M-14.9% | ||
| —— | -$117.25M+54.2% | -$117.25M+54.2% | -$117.25M+54.2% | -$117.25M+54.2% | ||
| —— | -$701.25M-109% | -$701.25M-109% | -$701.25M-109% | -$701.25M-109% | ||
| $1.73B-9.7% | —— | $36M— | $4.99B+41.1% | $1.92B-42.5% | ||
| —— | -$322.25M+61.9% | -$322.25M+61.9% | -$322.25M+61.9% | -$322.25M+61.9% | ||
| $93M+333% | $117M-93.5% | $292M-59.2% | $101M+125% | -$40M-126% | ||
| $0-100% | —— | —— | —— | $6.31B+80.8% | ||
| $173M-24.5% | $368M— | $84M-34.4% | $105M-23.4% | $229M+13.9% | ||
| $32M-90.7% | $4.41B+39.3% | $366M-43.6% | $154M-47.8% | $344M+153% | ||
| -$22M+92.7% | —— | -$14M-180% | —— | -$300M— | ||
| $2.57B-9.0% | $4.05B-34.5% | $4.22B+56.2% | $3.26B+614% | $2.82B+254% | ||
| $4.58B+15.7% | $4.72B+215% | $2.74B+198% | $6.55B+521% | $3.96B+501% | ||
| $88M+7.3% | $591M+1,938% | $359M-70.8% | $63M+800% | $82M-73.1% | ||
| $0-100% | —— | —— | —— | $6.31B+80.8% | ||
| $0-100% | —— | —— | —— | $6.31B+80.8% | ||
| $792M-79.4% | —— | $583M— | —— | $3.85B+225% | ||
| $2.45B+0.3% | $2.45B+2.7% | $2.44B+2.7% | $2.45B+2.7% | $2.44B+2.7% | ||
| -$284M+20.2% | -$43M-207% | -$38M-533% | -$21M+66.7% | -$356M+7.8% | ||
| -$127M+67.1% | —— | —— | -$517M— | -$386M+81.1% | ||
| $0-100% | —— | —— | $151M-96.7% | $2.05B+524% | ||
| $62M-16.2% | $45M-69.4% | $66M+100% | —— | $74M+124% | ||
| $72M-52.6% | $1.02B+135% | $178M-63.4% | $3.34B+33.5% | $152M-17.4% | ||
| $2.18B+23.0% | $4.5B-22.4% | $4B-34.0% | —— | $1.77B+359% | ||
| $2.18B+23.0% | $4.5B-22.4% | $4B-34.0% | —— | $1.77B+359% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pfizer generate?
- Pfizer (PFE) generated $12.6B in operating cash flow over the trailing twelve months.
- What is Pfizer's free cash flow?
- After $2.5B of capital expenditures, Pfizer's free cash flow was $12.5B over the trailing twelve months, up 26.6% year over year.
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
